Oncolytics Biotech (ONCY) Interest Expenses (2019 - 2026)
Oncolytics Biotech (ONCY) posted quarterly Interest Expenses of $40.1 million for Q4 2025, up 139779.33% year-over-year from N/an in Q4 2024, and up 166933.97% quarter-over-quarter from $23979.0 in Q3 2025.
Oncolytics Biotech (ONCY) Interest Expenses (2019 - 2026) Analysis & Trends
Oncolytics Biotech (ONCY) has reported Interest Expenses for 7 consecutive years, with $40.1 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Interest Expenses rose 139779.33% year-over-year to $40.1 million; the TTM figure through Dec 2025 stood at $40.1 million (up 39453.9% YoY), while the FY2025 annual figure was $40.1 million, up 10.81% from the prior year.
- Interest Expenses grew to $40.1 million in Q4 2025 per ONCY's latest filing, from $23979.0 in the prior quarter.
- Across five years, Interest Expenses topped out at $40.1 million in Q4 2025 and bottomed at -$103138.4 in Q4 2022.
- Historically, Interest Expenses has averaged $2.0 million across 5 years, with a median of $21332.1 in 2021.
- Annual changes were most pronounced in 2022 — Interest Expenses slumped 597.12% — and 2025, when it jumped 139779.33%.
- Oncolytics Biotech's Interest Expenses stood at $20747.3 in 2021, then plunged by 597.12% to -$103138.4 in 2022, then surged by 112.82% to $13221.6 in 2023, then soared by 116.57% to $28634.0 in 2024, then surged by 139779.33% to $40.1 million in 2025.
- Business Quant data shows ONCY's Interest Expenses at $40.1 million in Q4 2025, $23979.0 in Q3 2025, and $25259.9 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 82.05 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -4.89 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 20.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 93.62 Mn |
| 10 | Oncolytics Biotech | 101.16 Mn | 101.16 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.96 Mn |
| Jun 30, 2026 | 1.96 Mn |
| Dec 31, 2025 | 40.05 Mn |
| Dec 31, 2025 | 40.05 Mn |
| Sep 30, 2025 | 23,978.96 |
| Sep 30, 2025 | 23,978.96 |
| Jun 30, 2025 | 25,259.94 |
| Jun 30, 2025 | 25,259.94 |
| Mar 31, 2025 | 27,179.74 |
| Mar 31, 2025 | 27,179.74 |
| Dec 31, 2024 | 28,633.97 |
| Dec 31, 2024 | 28,633.97 |
| Sep 30, 2024 | 30,788.24 |
| Sep 30, 2024 | 30,788.24 |
| Jun 30, 2024 | 30,707.90 |
| Jun 30, 2024 | 30,707.90 |
| Mar 31, 2024 | 11,131.70 |
| Mar 31, 2024 | 11,131.70 |
| Dec 31, 2023 | 13,221.64 |
| Dec 31, 2023 | 13,221.64 |